Oppenheimer Forecasts Substantial Gains for Two 'Strong Buy' Stocks: Voyager Therapeutics and Kala Pharmaceuticals.

Oppenheimer predicts up to a 550% jump for Voyager Therapeutics and another biotech company due to their promising treatments for neurological diseases, including Alzheimer's. The lead clinical candidate, VY7523, has shown encouraging preclinical results in mouse models, and the company has launched a multiple ascending dose trial in patients with early-stage AD. Voyager is also advancing a gene therapy pipeline with its TRACER capsid technology, including a tau-silencing gene therapy for Alzheimer's. Both stocks carry a Strong Buy consensus rating across the board with substantial upside potential.

Voyager Therapeutics, Inc., a biotechnology company specializing in gene therapy and neurology diseases, is poised for substantial growth, according to a recent prediction by Oppenheimer. The lead clinical candidate, VY7523, has demonstrated encouraging preclinical results in mouse models, and the company has initiated a multiple ascending dose trial in patients with early-stage Alzheimer's disease (AD) [1].

Voyager's gene therapy pipeline, leveraging its TRACER capsid technology, includes a tau-silencing gene therapy for AD, which is in preclinical trial. Additionally, the company is developing a vectorized anti-amyloid antibody for AD, as well as gene therapies for Friedreich's ataxia and Parkinson's disease [1].

The company's collaboration and license agreements with major pharmaceutical companies such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., further bolster its potential [1].

Another biotech company, Tiziana Life Sciences, is also set to benefit from the promising treatments for neurological diseases. Tiziana's experimental monoclonal antibody, foralumab, has shown potential in reducing Alzheimer's-related inflammation in a patient with the disease [2]. The drug is being tested in clinical trials and has received expanded access approval from the FDA for use in patients with moderate Alzheimer's disease.

The University of Barcelona recently discovered new molecular mechanisms related to Alzheimer's cognitive decline, opening new therapeutic targets in the fight against the disease [3].

Both Voyager Therapeutics and Tiziana Life Sciences carry a Strong Buy consensus rating across the board with substantial upside potential. Investors and financial professionals should closely monitor these companies as they advance their promising treatments for neurological diseases.

References:
[1] https://ca.finance.yahoo.com/quote/VYGR/
[2] https://www.npr.org/sections/shots-health-news/2025/05/30/nx-s1-5407860/alzheimers-nasal-spray-experimental-treatment
[3] http://www.news-medical.net/news/20250526/Study-uncovers-new-molecular-mechanisms-linked-to-Alzheimers-cognitive-decline.aspx